RESPITE: Switching to Riociguat in Pulmonary Arterial Hypertension Patients With Inadequate Response to Phosphodiesterase-5 Inhibitors

European Respiratory Journal- United Kingdom

doi 10.1183/13993003.02425-2016

Full Text

Abstract

Available in

Date

Authors

Publisher

European Respiratory Society (ERS)

Related search

Phosphodiesterase Type 5 Inhibitors in the Treatment of Pulmonary Arterial Hypertension

Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology
2010English

Case Report: A Patient With Pulmonary Arterial Hypertension Transitioning From a PDE-5 Inhibitor to Riociguat

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2016English

Initial Riociguat Monotherapy and Transition From Sildenafil to Riociguat in Patients With Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling

Lung
PulmonaryRespiratory Medicine
2018English

Survival of Japanese Patients With Pulmonary Arterial Hypertension After the Introduction of Endothelin Receptor Antagonists and/or Phosphodiesterase Type-5 Inhibitors

Internal Medicine
Internal MedicineMedicine
2012English

A Focus on Riociguat in the Treatment of Pulmonary Arterial Hypertension

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

Single Arterial Occlusion to Locate Resistance in Patients With Pulmonary Hypertension

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2003English

Mortality-Related Risk Factors in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. The Importance of Response to Treatment

Open Journal of Respiratory Diseases
2012English

Riociguat Is a Novel Medication for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Medical Council
2016English

Plasma sFlt-1 Fluctuations in Response to Pulmonary Arterial Hypertension Treatment

Cardiovascular Pharmacology: Open Access
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy